Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

MeSH terms

• ADAM Proteins / blood
• ADAMTS13 Protein
• Adult
• Aptamers, Nucleotide / administration & dosage
• Aptamers, Nucleotide / adverse effects
• Aptamers, Nucleotide / therapeutic use*
• Catheter-Related Infections / etiology
• Combined Modality Therapy
• Consciousness Disorders / etiology
• Double-Blind Method
• Early Termination of Clinical Trials
• Epilepsy / etiology
• Female
• Humans
• Immunosuppressive Agents / therapeutic use
• Infusions, Intravenous / adverse effects
• Male
• Middle Aged
• Plasma Exchange
• Platelet Count
• Protein Binding / drug effects
• Protein Structure, Tertiary
• Purpura, Thrombotic Thrombocytopenic / complications
• Purpura, Thrombotic Thrombocytopenic / drug therapy*
• Purpura, Thrombotic Thrombocytopenic / physiopathology
• Purpura, Thrombotic Thrombocytopenic / therapy
• von Willebrand Factor / antagonists & inhibitors*
• von Willebrand Factor / physiology